Microbot Medical (MBOT) EBIT (2010 - 2026)

Microbot Medical (MBOT) has reported EBIT for 17 consecutive years, with -$4.3 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 43.0% year-over-year to -$4.3 million; the trailing twelve-month figure through Mar 2026 stood at -$16.0 million (down 30.83% YoY), and the FY2025 full-year result was -$14.7 million, down 26.82% from the prior year.
• EBIT retreated to -$4.3 million in Q1 2026 per MBOT's latest filing, from -$4.1 million in the prior quarter.
• Across five years, EBIT topped out at -$2.1 million in Q4 2023 and bottomed at -$4.3 million in Q1 2026.
• Historically, EBIT has averaged -$3.2 million across 5 years, with a median of -$3.2 million in 2022.
• The sharpest annual moves came in 2023 and 2024: EBIT soared 34.77% in 2023, then plunged 65.86% in 2024.
• Over 5 years, EBIT stood at -$3.1 million in 2022, then jumped by 32.59% to -$2.1 million in 2023, then slumped by 65.86% to -$3.4 million in 2024, then fell by 20.64% to -$4.1 million in 2025, then slipped by 4.4% to -$4.3 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$4.3 million, -$4.1 million, and -$3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.